Best Biopharma Outsourcing Companies in New Jersey, United States
The 196 best Biopharma Outsourcing companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: GenScript ProBio.
Our analysis of 50 Biopharma Outsourcing companies
$6.3b in tracked funding; 77% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in New Jersey
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | GenScript ProBio Provider of antibody discovery, bioanalytic, and contract based clinical plasmid manufacturing services | $411M | 41 mo ago | 177 | 2002 | Brian Min CEO | — | 1 partnership |
| 2 | Covance Lab R&D drug testing for biopharma, advancing therapeutic development | $250M | 63 mo ago | 10,718 | 1996 | — | 23 patents Frozen tissue microarray platforms and moisture‑controlled sample handling for biomedical analysis | — |
| 3 | Kashiv BioSciences Developer of biosimilar medicines 76Innovation top 12%Patents top 17%News top 20%Partners top 21% All 10 signals ▾Innovationtop 12% Patentstop 17% Newstop 20% Partnerstop 21% Fundingtop 24% Talenttop 27% Growthtop 30% Marketbottom 49% Globalbottom 41% Techbottom 39% Innovation: 284 patents (top 8% of patent-holders) · 188 filings since 2022 vs 95 in 2017-21 Patents: 284 patents matched (strict assignee match) · 188 filings since 2022 vs 95 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $222M | 5 mo ago | 235 | 2010 | Chintu Patel Co-Founder | 284 patents Protein purification and formulation technologies for therapeutic antibodies and small‑molecule drugs. | — |
| 4 | Indegene Suite solutions for payers and healthcare providers | $220M | 62 mo ago | 350 | 1998 | Anand Kiran Co-Founder & EVP of Global Operations | — | — |
| 5 | Catalent Provider of development, manufacturing, and packaging solutions for medicines and supplements | $202M | 68 mo ago | 1,900 | 2007 | Alessandro Maselli President & Chief Executive Officer | — | — |
| 6 | Evergreen Theragnostics Provider of radiopharmaceuticals manufacturing and regulatory services | $75M | 26 mo ago | 55 | 2019 | James Cook CEO | — | — |
| 7 | NPS Pharma Global pharmaceutical company committed to better health and a brighter future | $50M | 142 mo ago | 365 | 1986 | — | 433 patents GLP‑2 peptide therapeutics and ion‑channel modulators for short bowel syndrome treatment | — |
| 8 | Celgene Developer of therapies for treating cancer and inflammatory diseases | $45M | 100 mo ago | 4,891 | 1986 | Jerome Zeldis Chairman & CEO | 5,473 patents Design and synthesis of heteroaryl small‑molecule PROTACs targeting IRAK kinases for cancer therapy | — |
| 9 | Delsys Pharmaceutical Corporation Technology for pharmaceutical formulation development, manufacture and drug delivery | $40M | 313 mo ago | — | 1977 | David King CEO | — | — |
| 10 | Champion Oncology Oncology CRO providing preclinical and clinical research services globally | $37M | 135 mo ago | 230 230 → 186 (-19%) | 1985 | — | — | 1 launch |
| 11 | BioCentriq CDMO focused on cell and gene therapy based drug developmet | $29M | 29 mo ago | 75 | 2019 | — | — | 1 partnership |
| 12 | CCM Bio Develops novel drugs, companion diagnostics, and offers contract research, development, and manufacturing. | $25M | 33 mo ago | — | 2021 | Raj Chakrabarti Founder & CEO | — | — |
| 13 | Halo Pharma CDMO offering integrated drug development services | $25M | 137 mo ago | 450 | 2006 | — | — | — |
| 14 | Experic Provider of supplychain and packaging solutions for biopharma sector | $24M | 21 mo ago | 51 | 2019 | — | — | — |
| 15 | Laureate Biopharmaceutical Services Biologics CDMO, now a part of Patheon/Thermo Fisher | $20M | 185 mo ago | 106 | 1981 | James Mullen CEO | — | — |
| 16 | Guardian Drug Manufacturer of over-the-counter pharmaceutical and nutritional products | $10M | 100 mo ago | 87 | 1984 | Arvind Dhruv Founder & CEO | — | — |
| 17 | okCapsule Provider of personalized supplement manufacturing and supply chain solutions | $10M | 50 mo ago | 19 | 2019 | Noah Austin Co Founder and Chief Technology Officer | — | — |
| 18 | Conjupro Biotherapeutics Biopharmaceutical company offering diversified research and development solutions | $9M | 33 mo ago | 18 | 2017 | Qingxi Wang CEO | — | — |
| 19 | Diligent Provider of contract based clinical trial and quality management services | $8M | 37 mo ago | 24 | 2018 | — | 17 patents Data storage/search systems and tape emulation for open-system environments | — |
| 20 | Appco Pharma US-based pharmaceutical company specializing in drug development, manufacturing, and commercialization | $5M | 75 mo ago | 123 | 2014 | Rajendra Appalaneni Founding Member | — | — |
| 21 | Orthobond Functionalized anti-microbial surface coatings for medical devices | $3M | 45 mo ago | 16 | 2004 | — | 80 patents Antimicrobial polymer coatings for medical and industrial surfaces. | — |
| 22 | Inaedis Provider of biological drugs research and development services | $3M | 12 mo ago | — | 2022 | Maksim Mezhericher Founder & CEO | — | 1 award |
| 23 | Longevica Provider of research, clinical studies, technology, and development of drugs | $3M | 45 mo ago | — | 2009 | — | — | — |
| 24 | Ascendia Pharmaceutical Solutions CDMO providing formulation development, analytical, and manufacturing services for pharmaceutical and… | $2M | 12 mo ago | — | 2012 | Jim Huang Founder & CEO | — | — |
| 25 | Tharimmune Clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory… 14Growth top 27%Funding top 36%Talent top 38%News top 40% All 10 signals ▾Growthtop 27% Fundingtop 36% Talenttop 38% Newstop 40% Moatbottom 42% Globalbottom 39% Patentsbottom 34% Techbottom 22% Marketbottom 9% Innovationbottom 4% Growth: 3 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo Funding: Raised $2.1M across 4 rounds · 4 rounds over 2 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 7 mo ago | 1 | 2023 | Randy Milby CEO | 2 patents Nanoparticle-based drug delivery systems for immunotherapeutic applications | 1 launch |
| 26 | Soterius Provider of pharmacovigilance, medical affairs, and regulatory services for pharma | $2M | 75 mo ago | 38 | 2018 | Suneet Walia Founder & CEO | — | 2 job openings · 2 partnerships |
| 27 | ERG Provider of clinical research site services | $1M | 133 mo ago | 259 | 1998 | — | — | — |
| 28 | Apicore Traditional company offering contract manufacturing and custom synthesis services | $720K | 116 mo ago | 56 | 2003 | Ravishanker Kovi President & CSO | 78 patents Synthesis and polymorph development of small‑molecule pharmaceuticals and extended‑release formulations. | — |
| 29 | Provid Pharmaceuticals Developing MHC inhibition drugs for multiple sclerosis and autoimmune diseases | $400K | 142 mo ago | 5 | 2001 | Gary Olson President & CEO | — | — |
Top 12 Biopharma Outsourcing companies in New Jersey
#1
Acquired · Piscataway, New Jersey · founded 2010 · 235 employees$222.3Mraised▾
Developer of biosimilar medicines. It is an integrated biopharmaceutical company with capabilities in R&D, clinical, manufacturing, regulatory, and intellectual property.
- Dec 2025Conventional Debt$72.3M
- Apr 2025Conventional Debt$150M
#2
Public · Bridgewater, New Jersey · founded 2023 · 1 employees$2.1Mraised▾
Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for rare, inflammatory, and oncologic conditions. They are dedicated to improving the lives of patients through their portfolio of innovative treatments.
- Nov 2025Post IPO$545M
- Jun 2025Post IPO$2.5M
- Dec 2024Post IPO$2M
- Jun 2024Post IPO$2.1M
#3
Funding Raised · Princeton, New Jersey · founded 2022$3.1Mraised▾
Provider of biological drugs research and development services
- Jun 2025Grant (prize money)$1.2M
- May 2025Grant (prize money)$1.2M
- Dec 2023Grant (prize money)$312.6K
- Sep 2023Grant (prize money)$275K
#4
Series B · Cranbury, New Jersey · founded 2019 · 51 employees$24Mraised▾
Provider of supplychain and packaging solutions for biopharma sector
- Sep 2024Series B$15M
- Oct 2023Series B—
- Nov 2022Series B$14M
#5
Seed · North Brunswick, New Jersey · founded 2012$2.5Mraised▾
CDMO providing formulation development, analytical, and manufacturing services for pharmaceutical and biological companies. It offers customized formulations, analytical services, and GMP/cGMP manufacturing for clinical trial materials. The company specializes in nanotechnologies to address solubility challenges and develop pharmaceutical products. It provides services for small molecules, biologics, and gene deliveries, including sterile parenteral and oral solid dosage manufacturing. The company also conducts ICH stability studies and offers pre-formulation services.
- May 2025Seed$2.5M
#6
Acquired · Jersey City, New Jersey · founded 2019 · 55 employees$75.5Mraised▾
Provider of radiopharmaceuticals manufacturing and regulatory services
- Apr 2024Series C$26M
- Aug 2023Series B$15.5M
- Mar 2023Series B$15M
- Apr 2020Series A$19.5M
#7
Series C · Piscataway, New Jersey · founded 2002 · 177 employees$411Mraised▾
Provider of antibody discovery, bioanalytic, and contract based clinical plasmid manufacturing services
- Jan 2023Series C$224M
- Jun 2022Series B$37M
- Sep 2021Series A$150M
#8
Acquired · Newark, New Jersey · founded 2019 · 75 employees$29.2Mraised▾
CDMO focused on cell and gene therapy based drug developmet
- Jan 2024Series A$29.2M
#9
Public · Princeton, New Jersey · founded 1998 · 350 employees$220Mraised▾
Suite solutions for payers and healthcare providers. The payer solutions portfolio includes transformation, care management, member acquisition and engagement, healthcare analytics, and medicare analysis; and the ACO solutions portfolio comprises transformation services, outcomes improvement, patient engagement, and analytics. It also operates cloud-based platforms for customer engagement, member loyalty & retention, and care management.
- Apr 2021Series C$35.2M
- Feb 2021PE$200M
- Jan 2020PE$20M
- 2002PE—
#10
Acquired · Princeton, New Jersey · founded 1996 · 10718 employees$250.3Mraised▾
Lab R&D drug testing for biopharma, advancing therapeutic development. They navigate the complexities of drug development with scientific laboratory services. They offer solutions that inform every development phase and support targeted therapeutic indications, including emerging treatment modalities. Services include nonclinical development with toxicology, pharmacology, and metabolism expertise, central lab services for clinical trial data generation, and commercialization services for biomarker-driven trials and companion diagnostics. They expedite drug development and bring new therapies to patients faster through scientific and operational leadership, advanced technology, and global lab testing capacity. They provide actionable insights with quality data and expert analysis, adhering to compliance, privacy, and security standards. They support biopharmaceutical partners, investigator sites, and patients from drug discovery to clinical trial testing and diagnostic development and commercialization.
- Mar 2021Grant (prize money)$304.4K
- Nov 2013Venture Debt$250M
#11
Series A · Mount Laurel Township, New Jersey · founded 2021$25Mraised▾
Develops novel drugs, companion diagnostics, and offers contract research, development, and manufacturing. The company discovers and develops small molecules, gene therapies, biologics, and nanomedicines. It supports preclinical drug development and Chemistry, Manufacturing and Control (CMC) during trials through its in-house contract research, development, and manufacturing organization. The company also develops companion diagnostic tests and has partnered with scientific thought leaders for distributed and scalable innovation management.
- Aug 2023Series A$25M
#12
Acquired · Somerset, New Jersey · founded 2007 · 1900 employees$202.4Mraised▾
Provider of development, manufacturing, and packaging solutions for medicines and supplements. It offers services for oral dose forms, biologics, and specialty technologies. These services include formulation, bioavailability enhancement, and analytical solutions. The company also provides clinical supply forecasting, packaging, and distribution.
- Oct 2020Grant (prize money)$761.6K
- Feb 2020Conventional Debt$200M
- May 2015Grant (prize money)$1.6M
- 2007Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.